- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.80 Å
- Oligo State
- hetero-3-3-3-3-3-3-3-3-mer
- Ligands
- 18 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.3: 2 residues within 4Å:- Chain H: N.58
- Chain I: Y.57
No protein-ligand interaction detected (PLIP)NAG-NAG.4: 4 residues within 4Å:- Chain H: T.102, N.103, I.108, D.110
No protein-ligand interaction detected (PLIP)NAG-NAG.8: 4 residues within 4Å:- Chain H: R.162, I.164, N.167
- Chain V: R.278
No protein-ligand interaction detected (PLIP)NAG-NAG.11: 4 residues within 4Å:- Chain H: N.265, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)NAG-NAG.20: 2 residues within 4Å:- Chain A: Y.57
- Chain P: N.58
No protein-ligand interaction detected (PLIP)NAG-NAG.21: 4 residues within 4Å:- Chain P: T.102, N.103, I.108, D.110
No protein-ligand interaction detected (PLIP)NAG-NAG.25: 4 residues within 4Å:- Chain H: R.278
- Chain P: R.162, I.164, N.167
No protein-ligand interaction detected (PLIP)NAG-NAG.28: 4 residues within 4Å:- Chain P: N.265, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)NAG-NAG.37: 2 residues within 4Å:- Chain V: N.58
- Chain W: Y.57
No protein-ligand interaction detected (PLIP)NAG-NAG.38: 4 residues within 4Å:- Chain V: T.102, N.103, I.108, D.110
No protein-ligand interaction detected (PLIP)NAG-NAG.42: 4 residues within 4Å:- Chain P: R.278
- Chain V: R.162, I.164, N.167
No protein-ligand interaction detected (PLIP)NAG-NAG.45: 4 residues within 4Å:- Chain V: N.265, V.302, S.303, R.412
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.5: 8 residues within 4Å:- Chain C: D.56, N.58, F.114, T.115
- Chain D: W.88, D.89, T.94
- Chain H: N.107
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:D.56, C:N.58, C:T.115
NAG-NAG-BMA-MAN.22: 8 residues within 4Å:- Chain K: D.56, N.58, F.114, T.115
- Chain L: W.88, D.89, T.94
- Chain P: N.107
2 PLIP interactions:2 interactions with chain K- Hydrogen bonds: K:D.56, K:N.58, K:T.115
NAG-NAG-BMA-MAN.39: 8 residues within 4Å:- Chain Q: D.56, N.58, F.114, T.115
- Chain R: W.88, D.89, T.94
- Chain V: N.107
2 PLIP interactions:2 interactions with chain Q- Hydrogen bonds: Q:D.56, Q:N.58, Q:T.115
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.6: 8 residues within 4Å:- Chain D: E.20
- Chain H: V.104, T.105, N.118, S.120, Y.135, D.290
- Ligands: MAN.53
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.23: 8 residues within 4Å:- Chain L: E.20
- Chain P: V.104, T.105, N.118, S.120, Y.135, D.290
- Ligands: MAN.57
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.40: 8 residues within 4Å:- Chain R: E.20
- Chain V: V.104, T.105, N.118, S.120, Y.135, D.290
- Ligands: MAN.61
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.7: 5 residues within 4Å:- Chain H: Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.24: 5 residues within 4Å:- Chain P: Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.41: 5 residues within 4Å:- Chain V: Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.9: 6 residues within 4Å:- Chain H: N.204, T.206, S.244, E.245, I.247, H.321
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.26: 6 residues within 4Å:- Chain P: N.204, T.206, S.244, E.245, I.247, H.321
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.43: 6 residues within 4Å:- Chain V: N.204, T.206, S.244, E.245, I.247, H.321
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.10: 8 residues within 4Å:- Chain H: S.179, E.181, N.232, N.346, V.414, S.415
- Chain N: Q.1
- Ligands: NAG-NAG-BMA.17
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.27: 8 residues within 4Å:- Chain P: S.179, E.181, N.232, N.346, V.414, S.415
- Chain T: Q.1
- Ligands: NAG-NAG-BMA.34
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN.44: 8 residues within 4Å:- Chain F: Q.1
- Chain V: S.179, E.181, N.232, N.346, V.414, S.415
- Ligands: NAG-NAG-BMA.51
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.13: 16 residues within 4Å:- Chain C: R.103, I.104, G.106, V.107, V.108
- Chain D: N.44, N.45, P.60, G.61, S.62
- Chain H: T.267, R.296, H.299, N.301, S.381, R.412
7 PLIP interactions:2 interactions with chain H, 1 interactions with chain C, 4 interactions with chain D- Hydrogen bonds: H:R.296, H:R.296, C:G.106, D:N.44, D:N.44, D:N.45, D:G.61
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.30: 16 residues within 4Å:- Chain K: R.103, I.104, G.106, V.107, V.108
- Chain L: N.44, N.45, P.60, G.61, S.62
- Chain P: T.267, R.296, H.299, N.301, S.381, R.412
7 PLIP interactions:1 interactions with chain K, 2 interactions with chain P, 4 interactions with chain L- Hydrogen bonds: K:G.106, P:R.296, P:R.296, L:N.44, L:N.44, L:N.45, L:G.61
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.47: 16 residues within 4Å:- Chain Q: R.103, I.104, G.106, V.107, V.108
- Chain R: N.44, N.45, P.60, G.61, S.62
- Chain V: T.267, R.296, H.299, N.301, S.381, R.412
7 PLIP interactions:2 interactions with chain V, 1 interactions with chain Q, 4 interactions with chain R- Hydrogen bonds: V:R.296, V:R.296, Q:G.106, R:N.44, R:N.44, R:N.45, R:G.61
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.15: 5 residues within 4Å:- Chain H: M.112, N.355, S.357
- Ligands: NAG-NAG-BMA.14, NAG-NAG-BMA.16
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.32: 5 residues within 4Å:- Chain P: M.112, N.355, S.357
- Ligands: NAG-NAG-BMA.31, NAG-NAG-BMA.33
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.49: 5 residues within 4Å:- Chain V: M.112, N.355, S.357
- Ligands: NAG-NAG-BMA.48, NAG-NAG-BMA.50
No protein-ligand interaction detected (PLIP)- 9 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.52: 3 residues within 4Å:- Chain G: N.107, S.109, E.110
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:S.109, G:S.109
NAG.54: 1 residues within 4Å:- Chain H: N.308
No protein-ligand interaction detected (PLIP)NAG.55: 1 residues within 4Å:- Chain H: N.324
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:N.324
NAG.56: 3 residues within 4Å:- Chain O: N.107, S.109, E.110
2 PLIP interactions:2 interactions with chain O- Hydrogen bonds: O:S.109, O:S.109
NAG.58: 1 residues within 4Å:- Chain P: N.308
No protein-ligand interaction detected (PLIP)NAG.59: 1 residues within 4Å:- Chain P: N.324
1 PLIP interactions:1 interactions with chain P- Hydrogen bonds: P:N.324
NAG.60: 3 residues within 4Å:- Chain U: N.107, S.109, E.110
2 PLIP interactions:2 interactions with chain U- Hydrogen bonds: U:S.109, U:S.109
NAG.62: 1 residues within 4Å:- Chain V: N.308
No protein-ligand interaction detected (PLIP)NAG.63: 1 residues within 4Å:- Chain V: N.324
1 PLIP interactions:1 interactions with chain V- Hydrogen bonds: V:N.324
- 3 x MAN: alpha-D-mannopyranose(Non-functional Binders)
MAN.53: 1 residues within 4Å:- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.6
No protein-ligand interaction detected (PLIP)MAN.57: 1 residues within 4Å:- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.23
No protein-ligand interaction detected (PLIP)MAN.61: 1 residues within 4Å:- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.40
No protein-ligand interaction detected (PLIP)- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xu, K. et al., Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. (2018)
- Release Date
- 2018-05-16
- Peptides
- vFP20.01 Heavy Chain: AIW
vFP20.01 Light chain: BJX
PGT122 Heavy chain: CKQ
PGT122 Light Chain: DLR
VRC03 Light Chain: EMS
VRC03 Heavy Chain: FNT
Glycoprotein 41: GOU
Glycoprotein 120: HPV - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
hI
HW
3B
lJ
LX
4C
MK
mQ
7D
NL
nR
8E
RM
rS
6F
QN
qT
5G
DO
dU
1H
CP
cV
2
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.80 Å
- Oligo State
- hetero-3-3-3-3-3-3-3-3-mer
- Ligands
- 18 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 9 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x MAN: alpha-D-mannopyranose(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xu, K. et al., Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. (2018)
- Release Date
- 2018-05-16
- Peptides
- vFP20.01 Heavy Chain: AIW
vFP20.01 Light chain: BJX
PGT122 Heavy chain: CKQ
PGT122 Light Chain: DLR
VRC03 Light Chain: EMS
VRC03 Heavy Chain: FNT
Glycoprotein 41: GOU
Glycoprotein 120: HPV - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
hI
HW
3B
lJ
LX
4C
MK
mQ
7D
NL
nR
8E
RM
rS
6F
QN
qT
5G
DO
dU
1H
CP
cV
2